355 A case of macrophage activation syndrome (MAS) in cystic fibrosis  by Cresta, F. et al.
S148 13. Case Presentations Posters
355 A case of macrophage activation syndrome (MAS) in cystic
ﬁbrosis
F. Cresta1, G. Brigati1, A. Naselli1, R. Casciaro1, A. De Alessandri1, L. Minicucci1.
1Cystic Fibrosis Center G. Gaslini Institute, Genova, Italy
We describe the case of a cystic ﬁbrosis (CF) patient, age 11 yrs+8/12, FEV1 in
good health 60%, weight between 3rd and 25th percentile, chronically colonized by
methicillin-susceptible Staphylococcus aureus (MSSA). At the age of 10 yrs+9/12,
the patient underwent intravenous antibiotic therapy for respiratory exacerbation.
A week after onset he presented fever unresponsive to acetaminophen, alteration
of consciousness, emathemesis and melena. Blood tests performed showed: PLTs
47,000/mm3, ferritin 76,150 ng/dl, LDH 7863U/L, AST 642U/L, aPTT 91.4 s,
PT 21%, Fibrinogen 88mg/dl. These ﬁrst ﬁndings suggested an initial septic
shock so we changed intravenous antibiotic therapy: ciproﬂoxacin (30mg/kg/day),
amikacin (20mg/kg/day), teicoplanin (10mg/kg/day) and oseltamivir (120mg/day
for one week) after throat swab result (positive for AH1N1 virus). We also
performed blood culture (negative), chest x-ray (presence of an area of thickening
in the basal left), EGDS (evidence of fund hemorrhagic gastritis); abdominal
ultrasound, x-ray brain and MRI were normal. These ﬁndings and the persistence
of alterations of serum chemistry suggested the diagnosis of MAS and we started
intravenous therapy with octreotide, methylprednisolone only one dose of 30mg,
followed by 2mg/kg/day prednisone for 15 days followed by gradual scaling. In
a week we observed gradually resolution of clinical features with a complete
normalization of macrophage activation markers in 3 months. Currently the patient
has stable respiratory (last FEV1 64% pred) and nutritional conditions.
Conclusion: In our opinion AH1N1 virus is a possible trigger of MAS in this cystic
ﬁbrosis patient.
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Background: Aspergillus fumigatus is detected in cystic ﬁbrosis (CF) airway
ﬂuids with increasing frequency, but the pathophysiological signiﬁcance of this
pathogen, beyond allergic bronchopulmonary aspergillosis (ABPA), remains poorly
understood in CF.
Case report:We report a 11-year-old female CF patient who showed a rapid decline
of pulmonary function after successful eradication of Pseudomonas aeruginosa. In
parallel with this disease deterioration, A. fumigatus was detected in throat swabs
and sputum with positive galactomannan-antigens and A. fumigatus-antibodies (IgG,
IgM, IgA) detected, but without any signs of allergic sensitization (total IgE
not elevated) or ABPA (according to revised Nelson’s criteria). The patient was
co-colonized with Staphylococcus aureus and Stenotrophomonas maltophilia, but
without any obvious relationship to the current lung function decline. Several
attempts to stabilize the pulmonary function decline using IV antibiotics were
clinically unsufﬁcient. This situation inspired us to treat the patient with itraconazole
followed by voriconazole over seven months until the A. fumigatus-antibodies
disappeared. After this treatment period, lung function parameters stabilized.
Conclusion: Decline in lung function in CF patients without any association to
bacterial pathogens or other common causes might be due to Aspergillus fumigatus
infection. Antifungal treatments in such patients may improve lung function, also
in the absence of ABPA. Standardized clinical studies are required to evaluate the
effect of antigungal strategies in A. fumigatus-infected CF patients.
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Background: Colonisation with nontuberculous mycobacterial (NTM) disease in
children with cystic ﬁbrosis (CF) can lead to severe clinical deterioration. We
recently had to transplant a 12-year-old girl with clinical deterioration after infection
with Mycobacterium chelonae/immunogenum (MCI ). Risk factors for NTM are
allergic bronchopulmonary aspergillosis (ABPA) and long-term therapy with oral
steroids. The decision to treat NTM colonisation in a child with CF is challenging
and there is no proven treatment regimen available. We report two children where
MCI was detected and successfully eradicated.
Case reports: Two boys with CF (aged 10 and 16 years old) had ABPA and
were treated with oral steroids and itraconazole. After a few months, their sputum
revealed NTM (3×), and MCI was detected. As their lung function started to
deteriorate, therapy with linezolid (300mg bd), azithromycin (250mg od) and
inhaled amikacin (initial 250mg od, increased to 500 bd) was started for one
year, and vitamin B6 (50mg od) was given. After several months of therapy,
lung function could be stabilized and MCI was not anymore detectable in their
sputum or bronchoalveolar lavage (BAL). After one year, the antibiotic triple
therapy was stopped and MCI could not be detected in their sputum anymore.
As a side effect, one child had a mild transient neutropenia, and the other had mild
transient hoarseness after amikacin inhalation.
Conclusions: Early start of intensive treatment with linezolid, azithromycin and
inhaled amikacin for one year can eradicate MCI and stabilize lung function in
children with CF. As side effects can be severe, a close monitoring (initially weekly,
later every 2−4 weeks) is mandatory.
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Objectives: Signiﬁcant liver involvement affects only a minority of CF patients,
but end stage liver disease is one of the most common causes of death in CF after
cardiopulmonary failure. The adverse impact on lung health of poor nutritional
status and CFRD is well known.
Methods: Two CF patients [recipient A, 14 yrs (male) and B, 16 yrs (female)] were
referred to our liver transplant service with end stage liver disease. Patient A had
required liver transplant for coincidental alpha-1-antitrypsin deﬁciency at the age of
10 months. Both patients required pancreatic enzyme replacement therapy (PERT),
and insulin for CFRD and were signiﬁcantly malnourished. They needed high levels
of nutritional support, with one receiving nocturnal tube feeds, while the other
refused this recommendation. Both had anthropometrical habitus typical of patients
with end stage liver disease, displaying apparently normal BMI centiles (due to
hepatosplenomegaly) with very low mid upper arm circumference (MUAC) values.
Both patients were listed for, and received simultaneous liver and pancreas trans-
plants.
Results: See the table.
Recipient A Recipient B
Pre transplant Post transplant
14 months f/up
Pre transplant Post transplant
8 months f/up
BMI centile 35 98 46 40
MUAC cm (centile) 16.9 (<5th) 28.3 (75th) 20.9 (<5th) 25 (25th-50th)
Insulin, U/kg/day 0.5 0 2.1 0
Faecal elastase, mg/g <15 393 not available 480
PERT, IU lip/kg/day 9200 <1000 7600 0
Conclusions: Simultaneous liver and pancreas transplantation in cystic ﬁbrosis can
successfully resolve the need for insulin therapy in patients with CFLD and CFRD
and can also abolish, or signiﬁcantly reduce, the need for PERT. Nutritional status
also signiﬁcantly improves.
